Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilars Add “Urgency” To Medicare Payment Reforms – MedPAC Commissioner

Executive Summary

Developing alternatives to the ASP-based reimbursement system for Medicare Part B drugs may become increasingly important to ensure the program will benefit from lower-cost biosimilars, Georgetown’s Jack Hoadley points out.

You may also be interested in...



Reimbursement Briefs: Medicare Part B, PCORI Research

MedPAC will analyze alternatives for Medicare Part B to use “least costly alternative” payment method in lieu of legislative authority; OIG says Part B dispensing fees are too high; PCORI releases draft proposal on research review.

UnitedHealth Cancer Care Pilot Reduced Overall Costs Despite Higher Drug Spending

The bundled payment pilot program resulted in a 34% decrease in overall cancer treatment costs among participating medical centers despite a 179% increase in drug spending, according to results released July 8.

Lucentis vs. Avastin Cost Debate Resurfaces With Release Of Medicare Payment Data

Ophthalmologists are among the highest billing specialties listed in the Medicare Part B physician payment data, with Genentech’s Lucentis a strong driver of cost.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS056478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel